Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil versus dexmedetomidine sedation for arteriovenous fistula implantation
IRCT20200502047269N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- May 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of remifentanil and dexmedetomidine (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Pain score and Requires opioid administration. Started May 2020; status: completed.
02
Drugs
remifentanildexmedetomidine
Beyond the preview
Go deeper on IRCT20200502047269N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200502047269N1.